Clinical Scorecard: What Retina Specialists Have Learned From TRUCKEE
At a Glance
| Category | Detail |
|---|---|
| Condition | Neovascular Age-Related Macular Degeneration (nAMD) |
| Key Mechanisms | Faricimab demonstrates sustained anatomic improvements and longer treatment intervals. |
| Target Population | Patients with neovascular AMD, including treatment-naïve and previously treated individuals. |
| Care Setting | Real-world clinical practice |
Key Highlights
- Faricimab shows rapid improvement in anatomic parameters over 4.5 years.
- Treatment-naïve patients achieved treatment intervals of up to 10 weeks.
- Low rates of intraocular inflammation and endophthalmitis were reported.
- Patients switching from aflibercept experienced nearly 2-week interval extension after 9 injections.
- The study involved over 3,600 eyes and 2,900 patients.
Guideline-Based Recommendations
Diagnosis
- Monitor central subfield thickness, pigment epithelial detachment, subretinal fluid, and intraretinal fluid.
Management
- Consider faricimab for both treatment-naïve and previously treated patients.
Monitoring & Follow-up
- Assess for intraocular inflammation and other adverse events.
Risks
- Monitor for potential adverse events such as bilateral nonocclusive vasculitis.
Patient & Prescribing Data
Patients with neovascular AMD, including those who are treatment-naïve and those previously treated.
Faricimab allows for extended treatment intervals with continued anatomical improvement.
Clinical Best Practices
- Evolve treatment intervals based on patient response and comfort level with faricimab.
- Utilize faricimab in real-world settings to optimize patient outcomes.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.